---
document_datetime: 2025-12-02 05:00:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-viatris.html
document_name: tenofovir-disoproxil-viatris.html
version: success
processing_time: 0.1454077
conversion_datetime: 2025-12-28 08:45:06.357527
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan)

[RSS](/en/individual-human-medicine.xml/66050)

##### Authorised

This medicine is authorised for use in the European Union

tenofovir disoproxil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79009)
- [Related information](#related-information-597)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Tenofovir disoproxil Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tenofovir disoproxil Mylan.

For practical information about using Tenofovir disoproxil Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Tenofovir disoproxil Mylan and what is it used for?

Tenofovir disoproxil Mylan is used to treat adults and adolescents from 12 years of age infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). Tenofovir disoproxil Mylan is used in combination with other HIV medicines. In adolescents (from 12 to 18 years of age) its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI). For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Tenofovir disoproxil Mylan once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus's response to antiviral medicines.

Tenofovir disoproxil Mylan is also used to treat chronic (long-term) hepatitis B virus infection in adults and adolescents from 12 years of age. It is used in patients with liver damage but whose liver is still working properly (compensated liver disease). In adults, it can also be used for those patients with liver damage whose liver is not working properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B).

Tenofovir disoproxil Mylan contains the active substance tenofovir disoproxil. It is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Viread.

## How is Tenofovir disoproxil Mylan used?

Tenofovir disoproxil Mylan can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection or chronic hepatitis B.

Tenofovir disoproxil Mylan is available as tablets (245 mg) to be taken by mouth. The usual dose is one tablet taken once a day with food. The dose may need to be reduced or the medicine given less often in patients who have moderately or severely reduced kidney function. For more information, see the package leaflet.

## How does Tenofovir disoproxil Mylan work?

The active substance in this medicine, tenofovir disoproxil, is a 'prodrug' that is converted into tenofovir in the body.

Tenofovir is a nucleotide reverse-transcriptase inhibitor (NRTI). In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected. Tenofovir disoproxil Mylan, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Tenofovir disoproxil Mylan does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.

Tenofovir also interferes with the action of an enzyme produced by the hepatitis-B virus called 'DNA polymerase', which is involved in the formation of viral DNA. Tenofovir disoproxil Mylan stops the virus making DNA and prevents it from multiplying and spreading.

## How has Tenofovir disoproxil Mylan been studied?

Because Tenofovir disoproxil Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Viread. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Tenofovir disoproxil Mylan?

Because Tenofovir disoproxil Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Tenofovir disoproxil Mylan approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tenofovir disoproxil Mylan has been shown to have comparable quality and to be bioequivalent to Viread. Therefore, the CHMP's view was that, as for Viread, the benefit outweighs the identified risk. The Committee recommended that Tenofovir disoproxil Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tenofovir disoproxil Mylan?

The company that makes Tenofovir disoproxil Mylan will also ensure that all doctors who are expected to prescribe or use the medicine are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tenofovir disoproxil Mylan have also been included in the summary of product characteristics and the package leaflet.

## Other information about Tenofovir disoproxil Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Tenofovir disoproxil Mylan on 8 December 2016.

For more information about treatment with Tenofovir disoproxil Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Tenofovir disoproxil Mylan : EPAR - Summary for the public

English (EN) (94.78 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 19/12/2016

[View](/en/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-611)

български (BG) (121.62 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/bg/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_bg.pdf)

español (ES) (93.95 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/es/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_es.pdf)

čeština (CS) (120.07 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/cs/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_cs.pdf)

dansk (DA) (93.75 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/da/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (95.89 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/de/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (92.87 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/et/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (125.72 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/el/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_el.pdf)

français (FR) (94.65 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/fr/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (114.43 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/hr/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_hr.pdf)

italiano (IT) (93.07 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/it/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (116.83 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/lv/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (117.42 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/lt/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_lt.pdf)

magyar (HU) (116.22 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/hu/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_hu.pdf)

Malti (MT) (121.4 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/mt/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (94.46 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/nl/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_nl.pdf)

polski (PL) (121.01 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/pl/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_pl.pdf)

português (PT) (94.1 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/pt/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_pt.pdf)

română (RO) (116.97 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/ro/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (118.25 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/sk/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (113.38 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/sl/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (93.06 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/fi/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_fi.pdf)

svenska (SV) (93.39 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

19/12/2016

[View](/sv/documents/overview/tenofovir-disoproxil-mylan-epar-summary-public_sv.pdf)

Tenofovir disoproxil Mylan : EPAR - Risk management plan summary

English (EN) (194.6 KB - PDF)

**First published:** 20/09/2022

[View](/en/documents/rmp-summary/tenofovir-disoproxil-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Tenofovir disoproxil Viatris : EPAR - Product information

English (EN) (973.42 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 09/09/2025

[View](/en/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-918)

български (BG) (730.11 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/bg/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_bg.pdf)

español (ES) (618.49 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/es/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_es.pdf)

čeština (CS) (699.78 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/cs/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_cs.pdf)

dansk (DA) (710.41 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/da/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_da.pdf)

Deutsch (DE) (634.48 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/de/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_de.pdf)

eesti keel (ET) (618.46 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/et/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (827.24 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/el/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_el.pdf)

français (FR) (674.11 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/fr/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (793.37 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/hr/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_hr.pdf)

íslenska (IS) (697.75 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/is/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_is.pdf)

italiano (IT) (704.16 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/it/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (506.79 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/lv/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (572.78 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/lt/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_lt.pdf)

magyar (HU) (828.3 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/hu/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_hu.pdf)

Malti (MT) (704.96 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/mt/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (706.63 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/nl/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_nl.pdf)

norsk (NO) (522.75 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/no/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_no.pdf)

polski (PL) (872.43 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/pl/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_pl.pdf)

português (PT) (491.3 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/pt/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_pt.pdf)

română (RO) (971.25 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/ro/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (500.28 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/sk/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (476.08 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/sl/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_sl.pdf)

Suomi (FI) (715.73 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/fi/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_fi.pdf)

svenska (SV) (700.46 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

09/09/2025

[View](/sv/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000291054 05/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tenofovir disoproxil Viatris : EPAR - All Authorised presentations

English (EN) (45.63 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 26/07/2024

[View](/en/documents/all-authorised-presentations/tenofovir-disoproxil-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-407)

български (BG) (65.91 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/bg/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.14 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/es/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.25 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/cs/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.33 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/da/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.54 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/de/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.95 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/et/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.29 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/el/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (17.28 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/fr/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (82.79 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/hr/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (46.33 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/is/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.4 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/it/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (65.28 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/lv/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.61 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/lt/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.51 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/hu/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.27 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/mt/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.27 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/nl/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.45 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/no/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.59 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/pl/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.08 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/pt/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.71 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/ro/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.54 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/sk/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.74 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/sl/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (65.85 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/fi/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.66 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

26/07/2024

[View](/sv/documents/all-authorised-presentations/tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan) Active substance tenofovir disoproxil International non-proprietary name (INN) or common name tenofovir disoproxil Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AF07

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

HIV-1 infection

Tenofovir disoproxil 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.

In adults, the demonstration of the benefit of tenofovir disoproxil in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (&gt; 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (&lt; 10,000 copies/ml, with the majority of patients having &lt; 5,000 copies/ml).

Tenofovir disoproxil 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years.

The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.

Hepatitis B infection

Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:

- compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
- evidence of lamivudine-resistant hepatitis B virus.
- decompensated liver disease.

Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to &lt; 18 years of age with:

- compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.

## Authorisation details

EMA product number EMEA/H/C/004049

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 13/10/2016 Marketing authorisation issued 08/12/2016 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tenofovir disoproxil Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (138.42 KB - PDF)

**First published:** 19/07/2024

**Last updated:** 09/09/2025

[View](/en/documents/procedural-steps-after/tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tenofovir disoproxil Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (121.65 KB - PDF)

**First published:** 10/05/2017

**Last updated:** 19/07/2024

[View](/en/documents/procedural-steps-after/tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tenofovir disoproxil Mylan-H-C-PSUSA-00002892-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/134602/2020

English (EN) (146.09 KB - PDF)

**First published:** 03/04/2020

[View](/en/documents/scientific-conclusion/tenofovir-disoproxil-mylan-h-c-psusa-00002892-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tenofovir disoproxil Mylan : EPAR - Public assessment report

Adopted

English (EN) (678.62 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 19/12/2016

[View](/en/documents/assessment-report/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tenofovir disoproxil Mylan

Adopted

Reference Number: EMA/CHMP/659525/2016

English (EN) (77.67 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tenofovir-disoproxil-mylan_en.pdf)

#### News on Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Tenofovir disoproxil Viatris : EPAR - Product information - tracked changes

English (EN) (278.65 KB - DOCX)

**First published:** 09/09/2025

[View](/en/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-791)

български (BG) (212.21 KB - DOCX)

**First published:**

09/09/2025

[View](/bg/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_bg.docx)

español (ES) (205.82 KB - DOCX)

**First published:**

09/09/2025

[View](/es/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_es.docx)

čeština (CS) (210.28 KB - DOCX)

**First published:**

09/09/2025

[View](/cs/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (200.55 KB - DOCX)

**First published:**

09/09/2025

[View](/da/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (174.17 KB - DOCX)

**First published:**

09/09/2025

[View](/de/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (173 KB - DOCX)

**First published:**

09/09/2025

[View](/et/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (220.09 KB - DOCX)

**First published:**

09/09/2025

[View](/el/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_el.docx)

français (FR) (195.3 KB - DOCX)

**First published:**

09/09/2025

[View](/fr/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (220.03 KB - DOCX)

**First published:**

09/09/2025

[View](/hr/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (191.81 KB - DOCX)

**First published:**

09/09/2025

[View](/is/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_is.docx)

italiano (IT) (179.59 KB - DOCX)

**First published:**

09/09/2025

[View](/it/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (210.51 KB - DOCX)

**First published:**

09/09/2025

[View](/lv/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (168.1 KB - DOCX)

**First published:**

09/09/2025

[View](/lt/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (204.33 KB - DOCX)

**First published:**

09/09/2025

[View](/hu/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (188.63 KB - DOCX)

**First published:**

09/09/2025

[View](/mt/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (181.72 KB - DOCX)

**First published:**

09/09/2025

[View](/nl/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (195.22 KB - DOCX)

**First published:**

09/09/2025

[View](/no/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_no.docx)

polski (PL) (194.61 KB - DOCX)

**First published:**

09/09/2025

[View](/pl/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_pl.docx)

português (PT) (189.49 KB - DOCX)

**First published:**

09/09/2025

[View](/pt/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_pt.docx)

română (RO) (171.11 KB - DOCX)

**First published:**

09/09/2025

[View](/ro/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (198.32 KB - DOCX)

**First published:**

09/09/2025

[View](/sk/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (199.66 KB - DOCX)

**First published:**

09/09/2025

[View](/sl/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (192.05 KB - DOCX)

**First published:**

09/09/2025

[View](/fi/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (178.8 KB - DOCX)

**First published:**

09/09/2025

[View](/sv/documents/product-information-tracked-changes/tenofovir-disoproxil-viatris-epar-product-information-tracked-changes_sv.docx)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040490000) (initial marketing authorisation)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/09/2025

## Share this page

[Back to top](#main-content)